I. Neuromodulation treatment of gait disorders and falls Target of DBS for gait disorders and falls: PPN is an important node of gait-related brain network, and PPN-low frequency DBS is expected to improve gait disorders in PD. II. Treatment of non-motor symptoms 1. Treatment of dementia: Cholinergic inhibitors and amantadine can be added. 2. Treatment of psychiatric symptoms: control of precipitating factors; reduction of anti-Parkinson’s disease-related drugs; addition of atypical antipsychotics; cholinergic inhibitors may be added. 3.Treatment of postural hypotension: high salt diet; elevate the head of the bed; wear elastic stockings; pay attention to the effects after meals; add Midodrine treatment. 4. Treatment of pain: levodopa and dopamine receptor agonists improve PD pain. 5, fluctuation of non-motor symptoms: fluctuation of non-motor symptoms may be highly correlated with fluctuation of motor symptoms, most of which are aggravated in the off period and psychiatric symptoms, etc. are often aggravated in the on period. Corresponding treatment strategies need to treat motor symptoms themselves while adjusting the timing of the on/off period. 3. PD pharmacogenomics and precision medicine Based on personal genomic information, combined with proteomic, metabolomic and other related internal environmental information. We can design the best treatment plan for the patient in order to achieve a customized medical model that maximizes the therapeutic effect and minimizes side effects. In summary: The problems faced in the treatment of progressive PD mainly include disease progression with long-term treatment-related complications and the combined effects of movement disorders and non-motor symptoms. Treatment strategies for progressive PD include pharmacotherapy and neuromodulation therapy. In terms of pharmacological treatment, continuous dopamine-stimulated CDS therapy and pharmacogenomic studies are the direction of precise treatment. For neuromodulation therapy, DBS is an effective approach for progressive PD, and the selection of therapeutic targets needs to consider the differences in brain metabolic patterns and brain functional connectivity of different PD subtypes.